Sanofi Makes Comeback In Cancer Drug Market
Sanofi, the French pharmaceutical giant is confident that its reinstated itself in the global cancer drug market with the development of its immunotherapy drugs. It is also looking to get involved in the new area of molecular oncology.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
The company is working on a total of new cancer treatments but only one so far has made it to a review process in the European Union and the United States. That drug is the immunotherapy agent called Cemiplimab.
The cancer drug market is exceptionally competitive. According to forecasts compiled by Thomson Reuters, cancer immunotherapy has become the fastest-growing part of the $100 billion-a-year cancer drug market, and sales are expected to top $25 billion by 2021.
“We missed the immunology wagon in recent years but we are committed to catching up and we have a significant number of assets,” Jorge Insuasty, Sanofi’s global head of development said on Wednesday.
Many pharmaceutical companies are facing the challenge of coming up with smart combinations of drugs that can combat cancer.
Several firms have failed such as Switzerland’s Roche. Last month, the company failed a key combination trial in colorectal cancer.
Also US-based Incyte had failed to strengthen the effectiveness of Keytruda (created by Merck & Co) to treat skin cancer.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
